OMEPRAZOLE- omeprazole capsule, delayed release pellets
Golden State Medical Supply
Omeprazole delayed-release capsules, USP, are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.
Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.
Among patients who fail therapy, Omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section ].
Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.
Omeprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older.
Pediatric Patients 2 Years of Age to Adults
Omeprazole is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older.
The efficacy of omeprazole used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of Omeprazole may be considered.
Omeprazole is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months.
Omeprazole is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
Table 1 shows the recommended dosage of Omeprazole delayed-release capsules in adult patients by indication.
|Indication||Dosage of Omeprazole delayed-release capsules||Treatment Duration|
|Treatment of Active Duodenal Ulcer||20 mg once daily||4 weeks *|
|Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence||Triple Therapy Omeprazole delayed-release capsules 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three drugs twice daily||10 days In patients with an ulcer present at the time of initiation of therapy, continue Omeprazole delayed-release capsules 20 mg once daily for an additional 18 days for ulcer healing and symptom relief.|
|Dual Therapy Omeprazole delayed-release capsules 40 mg once daily Clarithromycin 500 mg three times daily||14 days In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of Omeprazole delayed-release capsules 20 mg once daily is recommended for ulcer healing and symptom relief.|
|Active Benign Gastric Ulcer||40 mg once daily||4 to 8 weeks|
|Treatment of Symptomatic GERD||20 mg once daily||Up to 4 weeks|
|Treatment of EE due to Acid-Mediated GERD||20 mg once daily||4 to 8 weeks †|
|Maintenance of Healing of EE due to Acid-Mediated GERD||20 mg once daily ‡||Controlled studies do not extend beyond 12 months.|
|Pathological Hypersecretory Conditions||Starting dose is 60 mg once daily; adjust to patient needs Daily dosages of greater than 80 mg should be administered in divided doses. Dosages up to 120 mg three times daily have been administered.||As long as clinically indicated. Some patients with Zollinger-Ellison syndrome have been treated continuously for more than 5 years.|
Table 2 shows the recommended dosage of Omeprazole delayed-release capsules in pediatric patients by indication.
|Indication||Omeprazole Delayed-release Capsules Dosage Regimen and Duration|
|Patient Age||Weight-Based Dose (mg)||Regimen and Duration|
|Treatment of Symptomatic GERD||2 to 16 years||10 to less than 20 kg: 10 mg||Once daily for up to 4 weeks|
|20 kg and greater: 20 mg|
|Treatment of EE due to Acid-Mediated GERD||2 to 16 years||10 to less than 20 kg: 10 mg||Once daily for 4 to 8 weeks *|
|20 kg and greater: 20 mg|
|Maintenance of Healing of EE due to Acid-Mediated GERD||2 to 16 years||10 to less than 20 kg: 10 mg||Once daily. Controlled studies do not extend beyond 12 months|
|20 kg and greater: 20 mg|
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.